Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Allergic Conjunctivitis Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Allergic Conjunctivitis Overview | 9 | 1 |
| Allergic Conjunctivitis Therapeutics under Development by Companies | 10 | 1 |
| Allergic Conjunctivitis Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Allergic Conjunctivitis Products under Development by Companies | 14 | 1 |
| Allergic Conjunctivitis Companies Involved in Therapeutics Development | 15 | 12 |
| Accolade Pharmaceuticals, LLC | 15 | 1 |
| Aldeyra Therapeutics Inc | 16 | 1 |
| Allergan Plc | 17 | 1 |
| Clevexel Pharma SA | 18 | 1 |
| Griffin Discoveries BV | 19 | 1 |
| NicOx S.A. | 20 | 1 |
| Ocular Therapeutix, Inc. | 21 | 1 |
| Ohr Pharmaceutical Inc. | 22 | 1 |
| Portola Pharmaceuticals, Inc. | 23 | 1 |
| Re-Pharm Limited | 24 | 1 |
| Sylentis S.A.U. | 25 | 1 |
| Xencor, Inc. | 26 | 1 |
| Allergic Conjunctivitis Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 23 |
| ADX-102 Drug Profile | 36 | 4 |
| AGN-229666 Drug Profile | 40 | 1 |
| cetirizine hydrochloride Drug Profile | 41 | 2 |
| CVXL-0074 Drug Profile | 43 | 1 |
| dexamethasone acetate SR Drug Profile | 44 | 5 |
| Drugs for Allergic Conjunctivitis Drug Profile | 49 | 1 |
| GD-134 Drug Profile | 50 | 1 |
| GD-136 Drug Profile | 51 | 1 |
| PRT-2761 Drug Profile | 52 | 1 |
| RP-0217 Drug Profile | 53 | 1 |
| Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma Drug Profile | 54 | 1 |
| SYL-116011 Drug Profile | 55 | 1 |
| XmAb-7195 Drug Profile | 56 | 2 |
| Zafi-2 Drug Profile | 58 | 1 |
| Allergic Conjunctivitis Dormant Projects | 59 | 2 |
| Allergic Conjunctivitis Discontinued Products | 61 | 1 |
| Allergic Conjunctivitis Product Development Milestones | 62 | 8 |
| Featured News &Press Releases | 62 | 1 |
| Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day | 62 | 1 |
| Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis | 62 | 2 |
| Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis | 64 | 1 |
| Dec 16, 2015: Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis | 64 | 1 |
| Nov 24, 2015: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis | 65 | 1 |
| Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis | 65 | 1 |
| Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis | 66 | 1 |
| Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial | 67 | 1 |
| Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis | 67 | 1 |
| Nov 24, 2014: Ora-CAC Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix s OTX-DP in Allergic Conjunctivitis | 68 | 1 |
| Nov 12, 2014: Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |